FDA Clearance News

COVID-19 Severity News

 
Forbes_2.png

Israeli Startups Join The Fight Against Coronavirus

Full story

Crouwdfund Insider.png

OurCrowd Portfolio Companies Pivot to Tackle Coronavirus Pandemic

Full story

MeMed to predict which COVID-19 patients will worsen

Full story

 

Media Coverage

Israeli firm advances diagnostic solutions for Covid-19

Full story

MeMed Receives CE Mark for Diagnostic Platform & Infection Assay

Full story

Test aiming to provide better treatment decisions receives

CE mark

Full story

MeMed Ramping Up Commercialization Efforts Following Regulatory Approvals

Full story

MeMed Receives CE for Advanced Diagnostic Test

Full story

MeMed secures CE mark for new point of need blood test

Full story

MeMed Receives CE-IVD Mark for Infectious Disease Test

Full story

Calcalist logo.png

MeMed Receives Regulatory Green Light for Test 

Full story

2020 OUrCrowd Global Investor Summit.png

ISRAEL21C: Israel races to find solutions for coronavirus

Full story

2020 OUrCrowd Global Investor Summit.png

Interview with Eran Eden, MeMed's CEO

Full story

World-Economic-Forum-Logo.png

MeMed Named "Technology Pioneer" by World Economic Forum

Full story

Study: MeMed's blood test distinguishes between bacterial, viral infections in children 

Full story

US DoD Commits Additional Funds to MeMed's Innovative Bacterial Versus Viral Test

Full story

Frost__Sullivan_Recognizes_MeMed-f62568d

Frost & Sullivan Recognizes MeMed with European Technology Leadership Award

Full story

The journey towards a disruptive blood test that can help address the threat of antibiotic resistance

Full story

Rapid blood test to 'cut antibiotic use'

Full story

FierceBiotechLogoNew.png

MeMed raises $70M for immune system-based infection diagnostics

Full story

Israeli Firm, US Department Of Defense To Fight Infectious Disease Together

Full story

MeMed Publishes New Data on Infectious Disease Dx, Plans 2018 Launch of POC Test

Full story

MeMed swiftly diagnoses if a disease is viral or bacterial 

Full story

Towards a world without antibiotics

Full story

(Hebrew)

globes_onLine-719158-58b8e7b65f9b58af5c9

MeMed raises $70M

Full story

New study shows MeMed's blood test accurately distinguishes bacterial and viral infections

Full story

Novel Assay Distinguishes Bacterial From Viral Infection in Kids

Full story

Infectious Disease Detective

Full story

MeMed Using $70M Funding Round to Develop Infection Test and POC Platform

Full story

The ultimate goal is to right-size antibiotic use

Full story

Israeli infection diagnostic start-up wins $9.2M funding boost

Full story

MeMed has received a contract from the Defense Threat Reduction Agency

Full story

MeMed Wins $4.1M DOD Grant toward Manufacturing of POC Platform

Full story

Viruses from Mars, bacteria from Venus

Podcast

(Hebrew)

MeMed Wins $9.2M DTRA Contract for PoC IVD to Reduce Antibiotic Misuse

Full story

MeMed Rolling Out Proteomic Test to Distinguish Between Bacterial, Viral Infections

Full story

A new blood test could stop doctors from over prescribing antibiotics

Full story

New Study Shows Superiority of MeMed's ImmunoXpert™ Over Procalcitonin, CRP, and HNL

Full story

MeMed has a rapid diagnostic that could help revolutionize the fight against drug-resistant bacteria

Full story

 

Press Releases

Fierce Medtech names MeMed as one of its ‘Fierce 15’ medical technology companies

March 7, 2022

MeMed raises $93M to accelerate commercialization of its  host immune-response product portfolio 

January 10, 2022

Clinical Data Published in Clinical Microbiology and Infection Support Use of MeMed’s Test in Reducing Antibiotic Overuse in Children 

December 1st, 2021

MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in
COVID-19 Patients

July 27, 2021

MeMed Key® Wins Red Dot Award for High Design Quality

April 21, 2021

Tanya Gottlieb, VP Scientific Affairs at MeMed, Appointed to the Board of the AMR Industry Alliance

April 19, 2021

MeMed and 360Dx Bring Together International Experts for a Timely Discussion on Predicting COVID-19 Severity Using the Host Immune Response

April 14, 2021

Riwat Lim Joins MeMed Team as Head of Commercial, Europe

January 19, 2021

Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S.

January 11, 2021

MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors

December 16, 2020

DiaSorin and MeMed Partner to Develop and Commercialize Novel Host Immune Response Based Diagnostic Solution 

September 8, 2020

Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients

July 23, 2020

MeMed Receives CE Mark for Two Pioneering Technologies: The MeMed BV™ Test and MeMed Key™ Point-of-Need Platform

June 2, 2020

MeMed Advances Diagnostic Solutions for COVID-19 Pandemic to Enable Enhanced Patient Management

Oct 29, 2019

 

News 

Diagnostics Industry Veteran Dr. Frédéric Sweeney Joins MeMed as Chief Business Development Officer
May 25, 2020

 

Events

Society of Critical Care Medicine
Feb 6 - 9   |   San Juan, PR

European Society of Paediatric Infectious Diseases
May 9 - 13   |   Athens, Greece

European Congress of Clinical Microbiology & Infectious Diseases
Apr 23 - 26   |   Lisbon, Portugal